Amneal Beats Estimates and Raises the Bar for 2026 — But Can It Outrun Its Debt Load and Deliver on a Billion-Dollar Biosimilar Bet?

Shares of Amneal Pharmaceuticals surged 7.3% to $20.49 in pre-market trading Thursday after the generic-drug maker posted second-quarter results that handily topped Wall Street expectations, extending a rally that has seen the stock climb 14% over the past five sessions.

• Revenue Jumped Faster Than Analysts Expected, and the Trend Is Accelerating. Q2 net revenue hit $796 million, a 10% year-over-year increase — well above the roughly 6% growth analysts had forecast. The market was expecting Amneal's revenue to grow 6% year on year , making the actual figure a significant upside surprise. Just as important: Q1 revenue grew only 4%, so the acceleration signals that new product launches and higher-margin specialty drugs are gaining traction, not fading.

• Profits Are Growing Even Faster Than Sales — the Mix Is Shifting. Adjusted EPS surged 20% to $0.30, beating the $0.23 consensus estimate. The higher EBITDA and earnings ranges point to improving mix and execution rather than simply counting on faster top-line growth.

Specialty segment revenue recorded $133 million in Q1, up 23% , and that momentum appears to have carried into Q2, lifting adjusted EBITDA 12% to $206 million. For shareholders, faster profit growth than revenue growth means the company is selling more higher-value medicines — a healthier, more durable pattern.

• Raised Guidance Signals Management Confidence — But Watch the Debt. Adjusted EBITDA is now projected at $740 million to $770 million, up from $720 million to $760 million.

Adjusted earnings per share are now expected to be 95 cents to $1.05, up from 93 cents to $1.03. The catch: Amneal is simultaneously digesting a $1.1 billion acquisition of Kashiv BioSciences to build out a copycat-biologics business. Combined net leverage is expected to hit roughly 3.7x adjusted EBITDA by end of 2026 , with management targeting below 3x by 2028. Stronger earnings help service that debt, but the margin for error is thin.

• The Biosimilar Gamble Defines What Amneal Becomes Next. By 2030, Amneal expects to have more than 12 commercial biosimilars and over 20 more products in the pipeline.

As the acquisition becomes accretive in 2027, the company expects sales to increase by between 7% and 13%. At ~20x midpoint 2026 EPS, the stock is pricing in solid execution but not yet a biosimilar windfall. The question now: can Amneal integrate Kashiv and deliver launches fast enough to justify the debt before generic pricing pressures catch up?